2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.18 LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with Mnsclc in an Israeli HMO

EP.11A.18 LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with Mnsclc in an Israeli HMO

Back to course

Pdf Summary

The study presented at WCLC 2024 focuses on treatment patterns and clinical outcomes in metastatic non-small cell lung cancer (mNSCLC) among patients in Israel, using data from the Maccabi Healthcare Services electronic database (January 2016–December 2022). It specifically examined patients with epidermal growth factor receptor wild-type (EGFR-WT), non-squamous (NSQ) mNSCLC who initiated second-line (2L) treatment.<br /><br />The study found that out of 886 patients who started first-line (1L) treatment, only 529 were identified as NSQ EGFR-WT without prior tyrosine kinase inhibitors (TKIs), and 33% (176 out of 529) progressed to 2L treatments. The median follow-up time was 5.5 months, with a median patient age of 67 years and 34% female patients. <br /><br />Commonly used initial treatments included platinum-doublet chemotherapy, followed often by anti-PD(L)1 monotherapy in the 2L setting. However, only 30% of these patients went on to receive third-line (3L) treatments. The study highlighted that clinical outcomes were generally poor, emphasizing an unmet need for more effective treatment options post-1L therapy. Specifically, it was noted that patients receiving anti-PD(L)1 chemotherapy combinations in 2L demonstrated numerically better outcomes across various metrics, including time to next treatment or death (TTNTD), progression-free survival (PFS), and overall survival (OS).<br /><br />Key conclusions from the study underline the challenges in the treatment of mNSCLC, with a significant portion of patients not receiving further treatment beyond initial therapies, underscoring the necessity for new, more effective treatment strategies post-1L for improved patient outcomes.

Asset Subtitle

Hasan Alhasani

Meta Tag

Speaker Hasan Alhasani

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

metastatic non-small cell lung cancer

mNSCLC

Israel

Maccabi Healthcare Services

epidermal growth factor receptor wild-type

EGFR-WT

second-line treatment

anti-PD(L)1 monotherapy

clinical outcomes

treatment strategies